243 related articles for article (PubMed ID: 27124210)
1. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
Péron J; Roy P; Ozenne B; Roche L; Buyse M
JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
3. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
4. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
Rauch G; Brannath W; Brückner M; Kieser M
Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
[TBL] [Abstract][Full Text] [Related]
5. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
6. Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.
Péron J; Lambert A; Munier S; Ozenne B; Giai J; Roy P; Dalle S; Machingura A; Maucort-Boulch D; Buyse M
J Natl Cancer Inst; 2019 Nov; 111(11):1186-1191. PubMed ID: 30838402
[TBL] [Abstract][Full Text] [Related]
7. A method for sequential analysis of survival data with nonproportional hazards.
Sooriyarachchi MR; Whitehead J
Biometrics; 1998 Sep; 54(3):1072-84. PubMed ID: 9750253
[TBL] [Abstract][Full Text] [Related]
8. Comparison of methods for estimating the attributable risk in the context of survival analysis.
Gassama M; Bénichou J; Dartois L; Thiébaut AC
BMC Med Res Methodol; 2017 Jan; 17(1):10. PubMed ID: 28114895
[TBL] [Abstract][Full Text] [Related]
9. A practical divergence measure for survival distributions that can be estimated from Kaplan-Meier curves.
Cox TF; Czanner G
Stat Med; 2016 Jun; 35(14):2406-21. PubMed ID: 26842429
[TBL] [Abstract][Full Text] [Related]
10. Analysis of time to event outcomes in randomized controlled trials by generalized additive models.
Argyropoulos C; Unruh ML
PLoS One; 2015; 10(4):e0123784. PubMed ID: 25906075
[TBL] [Abstract][Full Text] [Related]
11. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
12. A sequential testing approach to detecting multiple change points in the proportional hazards model.
He P; Fang L; Su Z
Stat Med; 2013 Mar; 32(7):1239-45. PubMed ID: 22933339
[TBL] [Abstract][Full Text] [Related]
13. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
Phadnis MA; Wetmore JB; Mayo MS
Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.
Wei Y; Royston P; Tierney JF; Parmar MK
Stat Med; 2015 Sep; 34(21):2881-98. PubMed ID: 26099573
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival with non-proportional hazards: results from the Dutch Gastric Cancer Trial.
Putter H; Sasako M; Hartgrink HH; van de Velde CJ; van Houwelingen JC
Stat Med; 2005 Sep; 24(18):2807-21. PubMed ID: 16134134
[TBL] [Abstract][Full Text] [Related]
16. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.
Royston P; Parmar MK
Stat Med; 2011 Aug; 30(19):2409-21. PubMed ID: 21611958
[TBL] [Abstract][Full Text] [Related]
17. Quantifying treatment effects using the personalized chance of longer survival.
Zhao YQ; Redman MW; LeBlanc ML
Stat Med; 2019 Dec; 38(28):5317-5331. PubMed ID: 31502297
[TBL] [Abstract][Full Text] [Related]
18. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
19. On proportional hazards assumption under the random effects models.
Xu R; Gamst A
Lifetime Data Anal; 2007 Sep; 13(3):317-32. PubMed ID: 17638076
[TBL] [Abstract][Full Text] [Related]
20. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
